JP2022537964A5 - - Google Patents
Info
- Publication number
- JP2022537964A5 JP2022537964A5 JP2021574283A JP2021574283A JP2022537964A5 JP 2022537964 A5 JP2022537964 A5 JP 2022537964A5 JP 2021574283 A JP2021574283 A JP 2021574283A JP 2021574283 A JP2021574283 A JP 2021574283A JP 2022537964 A5 JP2022537964 A5 JP 2022537964A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- stereoisomer
- acceptable salt
- compound according
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2019/091712 | 2019-06-18 | ||
| CN2019091712 | 2019-06-18 | ||
| US202063035381P | 2020-06-05 | 2020-06-05 | |
| US63/035,381 | 2020-06-05 | ||
| PCT/US2020/037853 WO2020257145A1 (en) | 2019-06-18 | 2020-06-16 | Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022537964A JP2022537964A (ja) | 2022-08-31 |
| JP2022537964A5 true JP2022537964A5 (cg-RX-API-DMAC7.html) | 2023-06-22 |
| JP7657740B2 JP7657740B2 (ja) | 2025-04-07 |
Family
ID=71575774
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021574283A Active JP7657740B2 (ja) | 2019-06-18 | 2020-06-16 | Jakキナーゼのピラゾロピリミジンスルホン阻害剤およびその使用 |
Country Status (18)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114026096B (zh) | 2019-06-18 | 2025-02-07 | 豪夫迈·罗氏有限公司 | 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途 |
| KR102767443B1 (ko) * | 2022-04-14 | 2025-02-12 | 한국화학연구원 | 퀴녹살린 카르복스아마이드 유도체 및 이를 유효성분으로 포함하는 교모세포종의 예방 또는 치료용 약학적 조성물 |
| EP4522598A1 (en) | 2022-05-11 | 2025-03-19 | PI Industries Ltd. | Bicyclic compounds and their use as pest control agents |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| JPH11508583A (ja) | 1995-07-06 | 1999-07-27 | ゼネカ・リミテッド | ペプチド系のフィブロネクチン阻害薬 |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (sh) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Postupak za sintezu analoga nukleozida |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| AU2002361992A1 (en) | 2001-12-20 | 2003-07-09 | Bayer Aktiengesellschaft | 1,4-dihydro-1,4-diphenylpyridine derivatives |
| SE0302487D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| CN101616921A (zh) * | 2007-01-30 | 2009-12-30 | 比奥根艾迪克Ma公司 | 1-H-吡唑并(3,4b)嘧啶衍生物及其作为有丝分裂激酶调节剂的用途 |
| AU2008211172A1 (en) * | 2007-01-30 | 2008-08-07 | Biogen Idec Ma Inc. | 1-H-pyrazolo(3,4B)pyrimidine derivatives and their use as modulators of mitotic kinases |
| AU2009259853A1 (en) | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine JAK inhibitor compounds and methods |
| BRPI0914404A2 (pt) | 2008-10-31 | 2019-03-06 | Genentech Inc | "compostos, composição farmacêutica e método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak quinase em um paciente" |
| UA110324C2 (en) * | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| HUE047441T2 (hu) | 2012-11-09 | 2020-04-28 | Medicines For Malaria Venture Mmv | Heteroaril-származékok és alkamazásaik |
| HRP20210935T1 (hr) | 2014-05-23 | 2021-08-06 | F. Hoffmann - La Roche Ag | Spojevi 5-kloro-2-difluorometoksifenil pirazolopirimidina koji predstavljaju inhibitore jak |
| TW201720828A (zh) | 2015-11-23 | 2017-06-16 | 赫孚孟拉羅股份公司 | 治療性化合物及組合物以及其使用方法 |
| WO2017140825A1 (en) | 2016-02-18 | 2017-08-24 | F. Hoffmann-La Roche Ag | Therapeutic compounds, compositions and methods of use thereof |
| MX2019007339A (es) | 2016-12-29 | 2019-09-06 | Hoffmann La Roche | Compuestos de pirazolopirimidina y metodos de uso de los mismos. |
| JP2020510061A (ja) | 2017-03-14 | 2020-04-02 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | ピラゾロクロロフェニル化合物、組成物及びその使用方法 |
| WO2018215390A1 (en) * | 2017-05-22 | 2018-11-29 | F. Hoffmann-La Roche Ag | Therapeutic compounds and compositions, and methods of use thereof |
| JP7256757B2 (ja) | 2017-05-22 | 2023-04-12 | エフ. ホフマン-ラ ロシュ アーゲー | 処置用化合物及び組成物、並びにその使用方法 |
| WO2019139714A1 (en) * | 2018-01-15 | 2019-07-18 | Genentech, Inc. | Pyrazolopyrimidine compounds as jak inhibitors |
| CA3127701C (en) * | 2019-01-25 | 2023-08-15 | Beijing Scitech-Mq Pharmaceuticals Limited | Acylamino bridged heterocyclic compound, and composition and application thereof |
| CN114026096B (zh) | 2019-06-18 | 2025-02-07 | 豪夫迈·罗氏有限公司 | 四唑取代的吡唑并嘧啶类jak激酶抑制剂及其用途 |
| EP3986899A1 (en) | 2019-06-18 | 2022-04-27 | F. Hoffmann-La Roche AG | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
-
2020
- 2020-06-16 JP JP2021574283A patent/JP7657740B2/ja active Active
- 2020-06-16 CR CR20210661A patent/CR20210661A/es unknown
- 2020-06-16 EP EP20739492.5A patent/EP3986901A1/en active Pending
- 2020-06-16 TW TW109120272A patent/TW202115068A/zh unknown
- 2020-06-16 WO PCT/US2020/037853 patent/WO2020257145A1/en not_active Ceased
- 2020-06-16 US US16/902,499 patent/US11453671B2/en active Active
- 2020-06-16 KR KR1020227000044A patent/KR20220024405A/ko not_active Ceased
- 2020-06-16 PH PH1/2021/552998A patent/PH12021552998A1/en unknown
- 2020-06-16 BR BR112021025618A patent/BR112021025618A2/pt not_active Application Discontinuation
- 2020-06-16 PE PE2021002182A patent/PE20220577A1/es unknown
- 2020-06-16 AU AU2020297415A patent/AU2020297415A1/en not_active Abandoned
- 2020-06-16 CN CN202080044750.2A patent/CN114008051B/zh active Active
- 2020-06-16 MX MX2021015319A patent/MX2021015319A/es unknown
- 2020-06-16 CA CA3140024A patent/CA3140024A1/en active Pending
- 2020-06-16 MA MA056518A patent/MA56518A/fr unknown
-
2021
- 2021-12-13 IL IL288957A patent/IL288957A/en unknown
- 2021-12-14 CL CL2021003341A patent/CL2021003341A1/es unknown
-
2022
- 2022-01-12 CO CONC2022/0000118A patent/CO2022000118A2/es unknown
- 2022-08-24 US US17/821,851 patent/US20230016791A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1360499A (zh) | 含有非诺贝特的药物组合物及其制备方法 | |
| CN1080120C (zh) | 药物组合物 | |
| CN113365998A (zh) | 用于parp抑制剂的吲哚并七元酰肟类似物 | |
| JP2023549226A5 (cg-RX-API-DMAC7.html) | ||
| JP2014523445A5 (cg-RX-API-DMAC7.html) | ||
| JP2019510787A5 (cg-RX-API-DMAC7.html) | ||
| JP2000500469A (ja) | 抗ニューモシスティス属作用物質としてのベンズアミドオキシム系プロドラッグ | |
| JPH07501539A (ja) | N,n’−ジアセチルシスチンの有機塩 | |
| JP2022507251A (ja) | P2x3調節剤としての置換イミダゾピリジン化合物の結晶形態およびそれらの使用 | |
| JP2023076632A5 (cg-RX-API-DMAC7.html) | ||
| US7208598B2 (en) | Derivatives of purine, their preparation process and pharmaceutical compositions containing them | |
| CN108358917B (zh) | 含有碱性稠环片段的咪唑并[1,2-a]吡啶-3-酰胺类化合物及其制备方法 | |
| JP2022527401A5 (cg-RX-API-DMAC7.html) | ||
| JP2018537513A5 (cg-RX-API-DMAC7.html) | ||
| JP2019530674A5 (cg-RX-API-DMAC7.html) | ||
| JP2020533296A5 (cg-RX-API-DMAC7.html) | ||
| Durham et al. | Spray dried aerosol particles of pyrazinoic acid salts for tuberculosis therapy | |
| JP2023512664A5 (cg-RX-API-DMAC7.html) | ||
| JP2023551467A (ja) | 5’-o-フェニルアセチルウリジン及び治療上の使用 | |
| Hegde et al. | Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS) | |
| Ueda et al. | Improvement in inhalation properties of theophylline and levofloxacin by co-amorphization and enhancement in its stability by addition of amino acid as a third component | |
| CN104546819A (zh) | 二咖啡酰奎宁酸在治疗系统性自身免疫性疾病中的用途 | |
| CN116437929A (zh) | 抗微生物化合物的吸入制剂 | |
| JP2018521001A (ja) | 化合物 (s)−3−{4−[5−(2−シクロペンチル−6−メトキシ−ピリジン−4−イル)−[1,2,4]オキサジアゾール−3−イル]−2−エチル−6−メチル−フェノキシ}−プロパン−1,2−ジオールの結晶形 | |
| WO2012110462A1 (en) | Liquid propellant-free formulation comprising an antimuscarinic drug |